Aquestive Therapeutics, Inc. (NASDAQ: AQST) reported a net loss of $22.9 million for the second quarter ended June 30, 2026, compared to a net loss of $13.5 million in the same period last year. The widening GAAP loss was driven largely by a one-time $11.7 million loss on extinguishment of debt related to its 13.5% Notes. Excluding this non-cash charge, the company’s adjusted net loss narrowed to $11.2 million. Total revenue rose 38% to $13.8 million from $10.0 million in Q2 2025, reflecting steady manufacturing output and growing royalty streams.

The financial results coincide with significant regulatory progress for Aquestive’s lead product candidate, Anaphylm™ (dibutepinephrine) sublingual film. The company completed the human factors validation study and pharmacokinetic study required to address deficiencies identified in the FDA’s Complete Response Letter dated January 30, 2026. Management reaffirms its guidance to resubmit the Anaphylm New Drug Application (NDA) in Q3 2026 and plans to request an expedited review upon submission.

Financial Performance

Revenue growth was broad-based, with both manufacturing and licensing segments contributing to the top-line increase. Manufacture and supply revenue climbed to $11.9 million from $9.6 million in Q2 2025, supported by higher Suboxone® revenues. License and royalty revenue also expanded, rising to $1.3 million from $0.8 million, primarily due to royalties from Zevra.

Operating expenses showed mixed trends. Research and development expenses decreased slightly to $4.0 million from $4.1 million, aided by lower development costs for the Anaphylm program. However, selling, general, and administrative (SG&A) expenses increased to $14.1 million from $12.7 million. This rise was attributed to higher legal fees of approximately $2.1 million and severance costs of approximately $1.4 million, partially offset by lower commercial spending of approximately $2.6 million.

Pipeline and Commercial Updates

Beyond Anaphylm, Aquestive is advancing its AdrenaVerse™ platform. The company completed a Phase 1 study for AQST-108, a topical epinephrine prodrug gel for dermatologic indications such as atopic dermatitis, with no safety concerns observed. Additionally, Libervant® (diazepam) buccal film remains tentatively approved in the U.S. for epilepsy patients aged 12 and older, with full approval expected following the expiration of orphan drug exclusivity in January 2027.

Manufacturing operations remained robust, with the company producing approximately 48 million doses in Q2 2026, up from approximately 37 million doses in the prior-year quarter. Aquestive continues to supply products for global collaborations, including Sympazan® for Cosette Pharmaceuticals, Inc., Ondif® for Hypera Pharma, and Emylif® for Zambon S.p.A.

What the Numbers Show

The divergence between GAAP and adjusted metrics highlights the impact of capital structure decisions on reported profitability. While the GAAP net loss widened significantly due to the debt extinguishment charge, the underlying operational loss narrowed when excluding this one-time item. Furthermore, the 38% revenue growth outpaced the modest decline in R&D spend, suggesting improved operational leverage in the manufacturing segment. The cash position stands at $98.5 million as of June 30, 2026, providing sufficient liquidity to fund operations through the anticipated NDA resubmission and potential launch phases.

Aquestive Therapeutics has reaffirmed its full-year 2026 sales guidance, setting the outlook at $46.000 million to $50.000 million against a market estimate of $50.584 million. The company’s decision to maintain this range indicates a cautious approach to revenue projections, as the upper limit of the guidance falls approximately $0.584 million short of analyst expectations. This affirmation provides clarity on the firm’s near-term financial trajectory, allowing investors to adjust their models based on the confirmed downside risk relative to consensus.

The guidance update serves as a key metric for assessing the company’s operational confidence in the current fiscal environment. By keeping the range unchanged from previous statements, Aquestive Therapeutics signals that no material positive developments have emerged to warrant an upward revision, nor have adverse conditions necessitated a downward adjustment. The gap between the top end of the guidance and the estimate highlights the importance of execution efficiency and potential cost management strategies to maximize profitability within the constrained revenue band.

Guidance Details

What the Numbers Show

The primary analytical observation is the persistent gap between Aquestive Therapeutics’ internal projections and external market expectations. With the high end of the guidance at $50.000 million versus an estimate of $50.584 million, the company is effectively pricing in a conservative scenario. This divergence suggests that management may be prioritizing certainty over optimism, potentially reflecting challenges in product adoption, competitive pressures, or supply chain constraints that are not yet fully resolved. Investors should monitor subsequent quarterly results to see if the company can narrow this gap through better-than-expected performance in later periods.